Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Health Research Projects

McGill University

$92,400.00

Microfluidic detection system for profiling multiple cancer biomarkers in serum with ultrahigh sensitivity and specificity

EF 2010-11

Résumé
In recent years, Canada has invested over a hundred million dollars on proteomics research, and one significant outcome has been the discovery of a number of candidate cancer biomarkers. It has also become clear that early diagnosis of cancer will rely on the detection of not one, but a panel of many of these protein biomarkers. However, current protein detection methods are labor intensive, allow the testing of only one biomarker at a time, and lack the sensitivity and specificity to be adapted for simultaneous analysis of many targets. This proposal describes the development of a new diagnostic device that allows parallel detection of a panel of protein biomarkers with ultrahigh sensitivity and specificity. It relies on use of a new class of polymeric nanospheres containing a very large number of signal-producing molecules. Detection will be carried out using electrochemiluminescence, (ECL), in which each of these units emits light catalytically with many turnovers, thus resulting in very bright emission. These nanospheres will be integrated into an advanced microfluidic device, designed for autonomous detection of multiple proteins using very small sample volumes. New protocols for sample preparation without compromising the integrity of the proteins will also be developed. Optimization of this new platform will be carried out on mouse models, then on plasma samples from breast cancer patients. Ultimately, we will detect cancer proteins in the blood of patients to evaluate our device. Together, this combination of chemistry, nanoscience, microfluidics, and cancer research constitutes, to our knowledge, a unique union of expertise in Canada. This collaborative effort will allow, for the first time, the creation of an inexpensive microfluidic detection system that miniaturizes and arrays protein assays for diagnostic applications. Following the discovery of biomarker panels for cancer diagnosis or any other disease, this technology can be developed and used in the clinic, at the doctor's office, and ultimately at home for self-testing and diagnosis. As such, we foresee that the development of such a technology will be essential to the establishment of preventive and personalized medicine.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
351330-2008
Name nom
Sleiman, Hanadi
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2008
Award amount
92400
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
3
Nb partie
3
Application title
Microfluidic detection system for profiling multiple cancer biomarkers in serum with ultrahigh sensitivity and specificity
Keyword
NSERC
Application summary
In recent years, Canada has invested over a hundred million dollars on proteomics research, and one significant outcome has been the discovery of a number of candidate cancer biomarkers. It has also become clear that early diagnosis of cancer will rely on the detection of not one, but a panel of many of these protein biomarkers. However, current protein detection methods are labor intensive, allow the testing of only one biomarker at a time, and lack the sensitivity and specificity to be adapted for simultaneous analysis of many targets. This proposal describes the development of a new diagnostic device that allows parallel detection of a panel of protein biomarkers with ultrahigh sensitivity and specificity. It relies on use of a new class of polymeric nanospheres containing a very large number of signal-producing molecules. Detection will be carried out using electrochemiluminescence, (ECL), in which each of these units emits light catalytically with many turnovers, thus resulting in very bright emission. These nanospheres will be integrated into an advanced microfluidic device, designed for autonomous detection of multiple proteins using very small sample volumes. New protocols for sample preparation without compromising the integrity of the proteins will also be developed. Optimization of this new platform will be carried out on mouse models, then on plasma samples from breast cancer patients. Ultimately, we will detect cancer proteins in the blood of patients to evaluate our device. Together, this combination of chemistry, nanoscience, microfluidics, and cancer research constitutes, to our knowledge, a unique union of expertise in Canada. This collaborative effort will allow, for the first time, the creation of an inexpensive microfluidic detection system that miniaturizes and arrays protein assays for diagnostic applications. Following the discovery of biomarker panels for cancer diagnosis or any other disease, this technology can be developed and used in the clinic, at the doctor's office, and ultimately at home for self-testing and diagnosis. As such, we foresee that the development of such a technology will be essential to the establishment of preventive and personalized medicine.